2025 miss and cautious 2026 targets erode investor confidence
18/02/26 -"Genmab’s full-year 2025 results showed both sales and adjusted operating profit falling short of market expectations. Despite this, double-digit sales growth was driven by strong contributions ..."
Pages
46
Language
English
Published on
18/02/26
You may also be interested by these reports :
20/02/26
After incorporating the 2025 financials, we have added a new forecast year to our model, which expects a continuation of growth at Novartis. The firm ...
20/02/26
Expanding margins despite moderate topline growth
18/02/26
After Bayer announced that it will settle most of the Roundup (glyphosate; herbicide) related class action suits (alleging Non-Hodgkin’s lymphoma, a ...
18/02/26
Genmab’s full-year 2025 results showed both sales and adjusted operating profit falling short of market expectations. Despite this, double-digit ...